EU OKs Mass. plant for Genzyme's Fabry disease drug

01/18/2012 | Reuters

The European Medicines Agency is permitting Sanofi division Genzyme to produce Fabry disease medicine Fabrazyme at a Framingham, Mass., facility. The approval "represents an important milestone in our manufacturing recovery and a path toward unconstrained supply for all patients," said Genzyme CEO and President David Meeker. The biotech firm still awaits FDA approval.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care